Condition: Solid Tumor · Sponsor: Chugai Pharmaceutical
This is a Phase Ia/Ib open-label, dose-escalation study to evaluate the safety and pharmacokinetics of ROSE12 as a single agent and in combination with other anti-tumor agents in patients with locally advanced or metastatic solid tumors. The study will consist of three parts: a dose-escalation part, a biopsy part (the part to evaluate biomarkers), and an expansion part.
This description comes directly from the study's public registry record.
Clinical trials information · only use Email · clinical-trials@chugai-pharm.co.jp
Always discuss trial participation with your own doctor first.
| University of Pennsylvania Perelman Center for Advanced Medicine | Philadelphia, Pennsylvania, United States | Recruiting |
| Rhode Island Hospital | Providence, Rhode Island, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| NEXT Oncology | Fairfax, Virginia, United States | Recruiting |
| Aichi Cancer Center | Nagoya, Aichi-ken, Japan | Recruiting |
| National Cancer Center Hospital East | Kashiwa-shi, Chiba, Japan | Recruiting |
| Kanagawa Cancer Center | Yokohama, Kanagawa, Japan | Recruiting |
| Kansai Medical University Hospital | Hirakata-shi, Osaka, Japan | Recruiting |
| Osaka International Cancer Institute | Osaka, Osaka, Japan | Recruiting |
| Kindai University Hospital | Sakai-shi, Osaka, Japan | Recruiting |
| Shizuoka Cancer Center | Nagaizumi-chō, Shizuoka, Japan | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05907980